The ATTR Amyloidosis Treatment industry is witnessing significant evolution as advancements in therapeutic options and increased disease awareness are shaping the landscape. Heightened R&D investments and innovation in targeted therapies have catalyzed the market’s expansion, creating ample market opportunities. This comprehensive analysis presents crucial insights on market size, growth drivers, evolving segments, and strategic moves by key market players through 2024 and 2025.

Market Size and Overview

The ATTR Amyloidosis Treatment Market is estimated to be valued at USD 4.14 Bn in 2025 and is expected to reach USD 7.52 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032.

The market growth is fueled by rising prevalence of transthyretin amyloidosis and increasing accessibility of novel therapies such as gene silencers and stabilizers. Moreover, expanding healthcare infrastructure and regulatory approvals have broadened the market scope, driving business growth and enhancing ATTR Amyloidosis Treatment Market Revenue streams across key regions.

Market Segments
The ATTR Amyloidosis Treatment Market analysis covers three core segments:
- Product Type: Predominantly includes stabilizers, gene silencers, and anti-amyloid agents. Stabilizers remain the dominant sub-segment with 2025 revenue exceeding USD 1.2 billion, while gene silencers represent the fastest-growing segment, registering a 12.5% CAGR due to recent approvals and improved patient compliance.
- Patient Type: Divided into hereditary ATTR and wild-type ATTR amyloidosis. Wild-type ATTR dominates usage volumes, supported by expanding geriatric populations, whereas hereditary ATTR is the fastest-growing segment owing to advances in genetic diagnostics and personalized medicine approaches.
- End-User: Encompasses hospital pharmacies, specialty clinics, and homecare settings. Hospital pharmacies remain the primary revenue source, but specialty clinics have shown rapid growth driven by outpatient infusion therapies and patient-centric care models implemented in 2024-2025.

‣ Get more insights on: ATTR Amyloidosis Treatment Market

‣ Get this Report in Japanese Language: ATTRアミロイドーシス治療市場

‣ Get this Report in Korean Language: ATTR아밀로이드증치료시장

‣ Read More Related Articles:  Global Rapid Influenza Diagnostic Tests Emerging as Important Tools for Pandemic Control and Prevention